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Abstract
Purpose Addition of rolapitant to standard antiemetic therapy
improved protection against chemotherapy-induced nausea
and vomiting (CINV) in phase 3 trials of patients receiving
highly emetogenic chemotherapy (HEC) or moderately
emetogenic chemotherapy (MEC). Here, we assessed the im-
pact of CINVon the daily lives of patients receiving HEC or
MEC using the Functional Living Index-Emesis (FLIE).
Methods In three double-blind phase 3 studies, patients re-
ceiving HEC or MEC were randomized 1:1 to receive oral
rolapitant 180 mg or placebo prior to chemotherapy plus 5-
hydroxytryptamine type 3 receptor antagonist and dexameth-
asone therapy. Patients completed the FLIE questionnaire on
day 6 of cycle 1. Endpoints included FLIE total score, nausea
and vomiting domain scores, and the proportion of patients
with no impact on daily life (total score >108 [range 18–126]).
We performed a prespecified analysis of the MEC/
anthracycline-cyclophosphamide (AC) study and a post hoc
analysis of two pooled cisplatin-based HEC studies.
Results In the pooled HEC studies, rolapitant significantly
improved the FLIE total score (114.5 vs 109.3, p < 0.001),
nausea score (55.3 vs 53.5, p < 0.05), and vomiting score
(59.2 vs 55.8, p < 0.001) versus control; similar results were
observed in the MEC/AC study for FLIE total score (112.7 vs
108.6, p < 0.001), nausea score (54.1 vs 52.3, p < 0.05), and
vomiting score (58.6 vs 56.3, p < 0.001). A higher proportion
of patients reported no impact on daily life with rolapitant than
with control in the MEC/AC study (73.2 vs 67.4, p = 0.027).
Conclusions Compared with control, rolapitant improved
quality of life in patients receiving HEC or MEC.
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Introduction
Chemotherapy-induced nausea and vomiting (CINV) is a de-
bilitating side effect of anticancer treatments associated with
substantial reductions in health-related quality of life (QoL)
[1–3]. Without antiemetic prophylaxis, >90 % of patients re-
ceiving highly emetogenic chemotherapy (HEC) and 30–
90% of patients receiving moderately emetogenic chemother-
apy (MEC) experience emesis [4]. Prior to the adoption of
current antiemetic prophylaxis strategies, patients consistently
ranked nausea and vomiting among the most distressing side
effects of chemotherapy, ranking these side effects worse than
fatigue, depression, or the impact of chemotherapy on their
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family or partner [5, 6]. The risk of developing CINV is pri-
marily related to the emetogenic potential of the chemothera-
peutic regimen, although factors including chemotherapy
dose, number of treatment cycles, and patient age and sex
may affect the risk [7].
Uncontrolled CINV can result in malnutrition, dehy-
dration, and electrolyte imbalance [8] and has been asso-
ciated with the development of anticipatory nausea and
vomiting with the potential to compromise adherence to
treatment [8, 9]. Fortunately, substantial progress in our
understanding of the neural mechanisms underlying CINV
has led to the development of highly effective therapeutic
approaches [9]. The use of 5-hydroxytryptamine type 3
(5-HT3) receptor antagonists (RAs), particularly when
combined with dexamethasone, has been found to effec-
tively reduce CINV in patients treated with HEC or MEC,
although CINV control was greatest in the acute phase
(≤24 h following chemotherapy) [4]; symptoms may per-
sist in the delayed phase (>24–120 h after chemotherapy
administration) in up to 50 % of patients [10–13]. The
addition of a neurokinin-1 (NK-1) RA to a 5-HT3 RA
and dexamethasone has improved CINV control through-
out the delayed phase, and this three-drug combination is
the recommended antiemetic prophylaxis regimen for pa-
tients receiving HEC and select patients with CINV risk
factors receiving MEC [4]. Despite substantial progress,
complete control of CINV, particularly nausea, in the de-
layed phase has proven difficult [14, 15]. Furthermore,
delayed-phase CINV has been found to have a greater
impact on QoL than CINV experienced only in the acute
phase [1, 2].
The Functional Living Index-Emesis (FLIE) is a validated
questionnaire designed to specifically address the impact of
CINVon patients’ daily lives [16, 17]. Validation of the FLIE
instrument is a sensitive and reliable measure of the impact
of CINVon QoL [16, 17]. Furthermore, use of the FLIE has
demonstrated that beyond a reduction in the physical symp-
toms of nausea and vomiting, effective antiemetic prophylaxis
reduces the negative impact of CINVon patients’ daily lives
[8, 18].
Rolapitant (VARUBI®, TESARO, Inc.) is a highly se-
lective, long-acting NK-1 RA indicated in combination
with other antiemetic agents in adults for the prevention
of delayed nausea and vomiting associated with initial and
repeat courses of emetogenic cancer chemotherapy [19].
Results of two phase 3 cisplatin-based HEC studies
(HEC-1 and HEC-2) [20] and one phase 3 MEC or
anthracycline and cyclophosphamide (AC)-based chemo-
therapy study [21] demonstrated that a single oral dose of
rolapitant (180 mg) taken before chemotherapy with a 5-
HT3 RA and dexamethasone resulted in superior protec-
tion against CINV in the delayed phase compared with
placebo plus a 5-HT3 RA and dexamethasone. Here, we
report on the impact of CINV on patients’ daily lives
using the FLIE in an analysis of the rolapitant phase 3
trials.
Methods
Three global, multicenter, randomized, parallel-group,
double-blind phase 3 studies (clinicaltrials.gov identifiers
NCT01500213, NCT01499849, and NCT01500226) were
conducted in compliance with the Internat ional
Conference on Harmonisation and Good Clinical
Practice (GCP) guidelines [20, 21]. Detailed methods
and results regarding the incidence of CINV were previ-
ously reported [20, 21].
Patients were required to be aged ≥18 years and to
have a Karnofsky performance score ≥60, a predicted life
expectancy of ≥4 months, and adequate bone marrow,
kidney, and liver function. Eligibility for the HEC studies
required patients to be naive to cisplatin and scheduled
to receive their first course of cisplatin ≥60 mg/m2.
Eligibility for the MEC/AC study required patients to
be naive to MEC and HEC and scheduled to receive
their first course of one or more of the following agents
alone or in combination: intravenous cyclophosphamide
(<1500 mg/m2), doxorubicin, epirubicin, carboplatin,
idarubicin, ifosfamide, irinotecan, daunorubicin, and/or
intravenous cytarabine (>1 g/m2). The study protocol
prespecified that ≥50 % of patients enrolled in the
MEC/AC study would receive AC-based chemotherapy
[21].
Prior to receiving study drug, patients were not permitted to
use any of the following medications: 5-HT3 RAs, phenothi-
azines, benzamides, domperidone, cannabinoids, NK-1 RAs,
or benzodiazepines within 48 h; palonosetron within 7 days;
or systemic corticosteroids or sedative antihistamines (e.g.,
dimenhydrinate or diphenhydramine) within 72 h of day 1,
with the exception of premedication for chemotherapy (e.g.,
taxanes). Patients with established nausea, vomiting, or both
were permitted to take rescue medication; those who used
rescue medication were considered failures for the efficacy
endpoint of complete response (no emesis and no use of res-
cue medication).
Treatment
Patients were stratified by sex and randomly assigned (1:1) to
either rolapitant 180 mg (rolapitant group) or placebo (control
group). All patients received 5-HT3 RA and dexamethasone
therapy (Fig. 1). Treatment blinding was maintained through-
out the studies.
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QoL assessment
The 18-item FLIE questionnaire [16, 17] comprises two
domains (nausea and vomiting); in each domain, the pa-
tient answers one question on the magnitude of the symp-
tom (nausea or vomiting) followed by eight questions to
assess the impact of the symptom on the patient’s ability
to enjoy meals/liquids, prepare meals/do household tasks,
perform daily functions, and engage in usual recreation/
leisure activities, as well as his/her willingness to spend
time with family and friends and the extent to which
symptoms have caused personal hardship [16, 17].
Patient responses are recorded using a seven-point visual
analogue scale (VAS), with higher scores corresponding
to a higher QoL and an average item score >6 defined as
no impact of CINV on daily life. Patients completed the
18-item FLIE questionnaire on day 6 (5-day recall) during
cycle 1. Responses to each of nine questions on the nau-
sea domain and nine questions on the vomiting domain
were marked on a 100-mm (seven-point) VAS. FLIE re-
sponses were summed to determine the total score (range
18–126) and the nausea and vomiting domain scores
(range 9–63). Higher scores indicate a greater ability to
maintain daily life. The proportion of patients with no
impact on daily life, defined as an average item score
>6 on the seven-point VAS (FLIE total score >108) [16,
17], was also determined. If ≥5 questions were answered
in a domain, the subtotal score for the domain was calcu-
lated as Sum of item scoresNumber of questions answered 9. If more than four of
nine questions were missed in a domain, subtotal and total
scores were considered missing [17].
Statistical analysis
Data were analyzed for all randomized patients in the modi-
fied intent-to-treat (MITT) population (patients who received
at least one dose of study drug at a GCP-compliant site) who
had a valid FLIE questionnaire obtained on day 6.
Prespecified analyses were performed for the MEC/AC study,
and post hoc analyses were performed for the pooled HEC
studies. p values <0.05 were considered statistically signifi-
cant and were not adjusted for multiplicity. Treatment com-
parisons were performed between the FLIE total score and
nausea and vomiting domain scores using an analysis of var-
iance model with terms for sex and study (pooled HEC anal-
ysis) in the model. For the endpoint of no impact on daily life,
treatment comparisons were performed using the Cochran-
Mantel-Haenszel χ2 test stratified by sex and study (pooled
HEC analysis). These analyses were not prospectively
powered to demonstrate statistical significance.
Results
Patients
The MITT populations comprised 1070 patients in the
pooled HEC studies and 1332 patients in the MEC/AC
Rolapitant 180 mg orally day 1 +
Granisetron 2 mg orally days 1–3 +
Dexamethasone 20 mg orally day 1
(n=684)MEC/AC trial
N=1369 Randomized 1:1 
Placebo orally day 1 +
Granisetron 2 mg orally days 1–3 +
Dexamethasone 20 mg orally day 1
(n=685)
Rolapitant 180 mg orally day 1 +
Granisetron 10 µg/kg intravenously day 1 +
Dexamethasone 20 mg orally day 1 +
Dexamethasone 8 mg orally twice daily days 2–4
HEC1 (n=266), HEC2 (n=278)HEC trials
HEC1: N=532, HEC2: N=555
Randomized 1:1 Placebo orally day 1 +
Granisetron 10 µg/kg intravenously day 1 +
Dexamethasone 20 mg orally day 1 +
Dexamethasone 8 mg orally twice daily days 2–4








Fig. 1 Treatment schema. In the HEC and MEC/AC trials, patients
received a single oral dose of rolapitant 180 mg or matching placebo
capsules 1–2 h prior to the administration of chemotherapy. In the HEC
trials, all patients received granisetron 10 μg/kg intravenously and
dexamethasone 20 mg orally prior to the administration of
chemotherapy on day 1; dexamethasone 8 mg orally twice daily was
administered on days 2–4. In the MEC/AC trial, all patients received
granisetron 2 mg orally plus dexamethasone 20 mg orally prior to
chemotherapy administration on day 1; granisetron 2 mg orally was
administered once daily on days 2 and 3. In the HEC and MEC/AC
trials, patients receiving taxanes were administered dexamethasone
accord ing to the package inse r t . AC an thracyc l ine and
cyclophosphamide-based chemotherapy, HEC highly emetogenic
chemotherapy, MEC moderately emetogenic chemotherapy, MITT
modified intent-to-treat
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study. Randomized and MITT populations are detailed in
Fig. 1. Patient baseline characteristics were balanced be-
tween rolapitant and control groups (Table 1). The major-
ity of patients in the cisplatin-based HEC studies were
male (63 %), and the most commonly diagnosed malig-
nancy was lung cancer (44 %). In the MEC/AC study,
most patients were female (80 %) and breast cancer was
the most commonly diagnosed malignancy (63 %); pa-
tients received a range of chemotherapies, with 53 % re-
ceiving AC-based chemotherapy (now classified as HEC
[4]), 30 % receiving carboplatin-based chemotherapy, and
17 % receiving other agents.
Quality of life
Patients in the rolapitant group reported a significantly higher
FLIE total score than patients in the control group in the
pooled HEC studies (mean difference = 5.2; 95 % confidence
interval [CI] 2.6–7.9; p < 0.001) and in the MEC/AC study
(mean difference = 4.1; 95 % CI 1.7–6.5; p < 0.001; Fig. 2a).
A significant improvement in the nausea domain score was
observed with rolapitant versus control in the pooled HEC
studies (mean difference = 1.8; 95 % CI 0.2–3.4; p = 0.020)
and the MEC/AC study (mean difference = 1.8; 95 % CI 0.3–
3.3; p = 0.019; Fig. 2b), as well as in the vomiting domain
Table 1 Baseline demographics
and patient characteristics of the
MITT population
Pooled HEC trials MEC/AC trial
Characteristic Rolapitant Control Rolapitant Control
(n = 535) (n = 535) (n = 666) (n = 666)
Age, years
Median (min, max) 59 (21, 86) 59 (18, 90) 58 (22, 86) 56 (22, 88)
Sex, n (%)
Male 337 (63) 336 (63) 135 (20) 130 (20)
Female 198 (37) 199 (37) 531 (80) 536 (80)
Race, n (%)
White 404 (76) 391 (73) 508 (76) 512 (77)
Black/African American 4 (1) 6 (1) 24 (4) 29 (4)
Asian 95 (18) 97 (18) 92 (14) 84 (13)
Other/multiracial/unknown 32 (6) 41 (8) 42 (6) 41 (6)
Geographic region, n (%)
North America 59 (11) 64 (12) 216 (32) 229 (34)
Central/South America 65 (12) 71 (13) 31 (5) 32 (5)
Europe 306 (57) 299 (56) 312 (47) 299 (45)
Asia/South Africa 105 (20) 101 (19) 107 (16) 106 (16)
Alcohol consumption (drinks/week), n (%)a
0 to ≤5 493 (93)b 483 (91)c 636 (96)d 625 (94)
>5 37 (7)b 50 (9)c 29 (4)d 41 (6)
Primary tumor site, n (%)
Breast 12 (2) 26 (5) 417 (63) 428 (64)
Colon/rectum 2 (<1) 0 (0) 38 (6) 27 (4)
Head and neck 97 (18) 100 (19) 5 (1) 6 (1)
Lung 235 (44) 232 (43) 102 (15) 118 (18)
Ovary 33 (6) 31 (6) 33 (5) 23 (3)
Stomach 34 (6) 34 (6) 8 (1) 9 (1)
Uterine 11 (2) 15 (3) 14 (2) 18 (3)
Other tumors 111 (21) 97 (18) 49 (7) 37 (6)
AC anthracycline and cyclophosphamide-based chemotherapy, HEC highly emetogenic chemotherapy, MEC
moderately emetogenic chemotherapy, MITT modified intent-to-treat
a Based on patient self-reports
b n = 530
c n = 533
d n = 665
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score in the pooled HEC studies (mean difference = 3.4; 95 %
CI 2.1–4.7; p < 0.001) and the MEC/AC study (mean differ-
ence = 2.3; 95 % CI 1.1–3.4; p < 0.001; Fig. 2c).
The proportion of patients with no impact on daily life,
defined as FLIE total score >108 (i.e., average item score >6
on the seven-point VAS), was greater in the rolapitant group
than in the control group in the pooled HEC studies andMEC/
AC study. Differences reached statistical significance in the
MEC/AC study (odds ratio [OR] = 1.3; 95 % CI 1.0–1.7;
p = 0.027), as previously reported [21], but not in the pooled
HEC studies (OR = 1.3; 95 % CI 1.0–1.7; p = 0.082; Fig. 2d).
Figure 3 shows the distribution of FLIE scores for patients in
the rolapitant and control groups in the pooled HEC studies
and the MEC/AC study. Separation of the curves illustrates
that a higher percentage of patients in the rolapitant group than
in the control group achieved an improved FLIE total score,
nausea domain score, and vomiting domain score in both the
pooled HEC studies and the MEC/AC study.
Discussion
Results from the FLIE questionnaire, a validated patient-
reported outcome instrument [16, 17], demonstrated the
efficacy of rolapitant in reducing the negative impact of
CINVon patients’ daily lives. Significant improvements were
observed in the FLIE total score and the nausea and vomiting
domain scores for patients in the rolapitant versus control
group. In these analyses, improvements relative to control
were similar for patients in the HEC and MEC/AC studies.
Improvements observed on the nausea domain with rolapitant
were notable, as nausea, especially in the delayed phase, has
proven more difficult to control than vomiting [14, 15].
Improvements in patients’ daily lives have also been
reported in studies of netupitant and aprepitant, two other
NK-1 RAs, using the FLIE questionnaire [10, 12, 18, 22,
23]. Recently, in a study of patients receiving AC-based
chemotherapy, the proportion of patients reporting no im-
pact on daily life overall and on the nausea and vomiting
domains was significantly greater with a netupitant regi-
men compared with control [22]. Significant improve-
ments over standard therapy in the proportion of patients
reporting no impact on daily life have also been observed
in studies of aprepitant [10, 12, 18, 23]. Whereas im-
provements on the nausea domain have been observed
with an aprepitant regimen over control in patients receiv-
ing cisplatin [18], this has not been achieved in some












































































































































Fig. 2 FLIE outcome
assessments. aMean FLIE total
score (range 18–126), b mean
nausea domain score, c mean
vomiting domain score (range 9–
63), and d percentage of patients
with no impact on daily life. Error
bars represent 95 % CIs.
Presented n values are based on
patients who had a valid FLIE
questionnaire obtained on day 6.
*Statistically significant
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In the rolapitant studies, the proportion of patients reporting
no impact of CINV on daily life overall was significantly
greater in the rolapitant group than in the control group in
the MEC/AC study (p = 0.027) [21], but significance on this
measure was not reached in the pooled HEC studies
(p = 0.082). It is unknown whether differences in the chemo-
therapy received (i.e., cisplatin vs MEC/AC) and/or other
CINV risk factors (i.e., proportion of male vs female patients)
may have contributed to differences on this measure. It should
be considered that patients had access to rescue medications
throughout the 5-day postchemotherapy period in these trials;
rescue medication use would mitigate symptoms of nausea
and vomiting, rendering improvements in QoL more difficult
to detect.
The National Comprehensive Cancer Network evidence-
based guidelines recommend NK-1 RA triple therapy to pro-
tect against CINV in patients with cancer receiving HEC and
in selected patients receiving MEC. Rolapitant has recently
been endorsed (category 1 recommendation) as part of an
effective NK-1 RA triple regimen [4]. In phase 3 studies,
complete response in the delayed phase (the primary end-
point) in the rolapitant and control groups was 71 and 60 %,
respectively, in the pooled HEC studies (p < 0.001) and 71 and
62%, respectively, in the MEC/AC study (p < 0.001) [20, 21].
Despite a relative risk reduction of 21–36 % with rolapitant
relative to control in patients administered HEC or MEC, a
portion of rolapitant-treated patients still experienced delayed-
phase CINV [20, 21]. Since rolapitant blocks >90 % of NK-1
receptors in the brain for at least 5 days [24], it is likely that
other biochemical pathways contribute to delayed-phase
CINV. This underscores the challenge of providing every pa-
tient with complete CINV protection throughout the delayed
phase.
Although even greater control of nausea and vomiting may
be possible, the progress made in protecting against CINVand
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Fig. 3 Distribution of FLIE
scores: The x-axes represent a
range of FLIE scores. a
Percentage of patients achieving
FLIE total score >x in the pooled
HEC studies and b the MEC/AC
study. c Percentage of patients
achieving nausea domain score
>x in the pooled HEC studies and
d the MEC/AC study. e
Percentage of patients achieving
vomiting domain score >x in the
pooled HEC studies and f the
MEC/AC study. Presented n
values are based on patients who
had a valid FLIE questionnaire








90 Support Care Cancer (2017) 25:85–92
noteworthy. In a study reported in 1983 by Coates et al. [5],
vomiting was ranked by patients as the first and nausea as the
second most troublesome chemotherapy-associated side ef-
fects. In contrast, in a 2014 study [25], Russo et al. reported
that nonphysical side effects such as “affects my family or
partner” or “constantly tired” were ranked as the most severe
patient-perceived side effects; in addition, vomiting was no
longer considered a major issue, although nausea remained
among the top 10 patient-perceived side effects.
Nausea, even in the absence of vomiting, has been shown
to adversely affect dietary intake and contribute to malnutri-
tion and weight loss [26]. Patients’ nutritional status, as
assessed by the Patient-Generated Subjective Global
Assessment, a tool that identifies malnutrition in ambulatory
oncology patients, was shown to predict the magnitude of
change in QoL [27]. Future studies may consider using this
tool in combination with the FLIE to explore the impact of
rolapitant on nutritional status and assess the contribution that
changes in nutritional status may have on QoL outcomes.
A limitation of this study is that, although the FLIE ques-
tionnaire has been validated and used widely in QoL research
associated with antiemetic therapies, the questions are brief
and do not address other side effects that patients may expe-
rience (e.g., fatigue). In addition, as patients did not complete
the FLIE questionnaire at baseline, improvement over time
within the same arm could not be evaluated, although it should
be noted that the goal of this clinical trial was to assess
between-group differences in mean FLIE scores (nausea,
vomiting, and total) and in the proportion of patients achiev-
ing a total FLIE score >108.
In summary, the addition of rolapitant, which provided su-
perior protection against delayed-phase CINV compared with
control in phase 3 studies [20, 21], reduced the negative im-
pact of CINVon the QoL of patients receiving HEC or MEC.
These results support the benefit of adding rolapitant to a 5-
HT3 RA and dexamethasone to improve the daily lives of
patients with cancer who are administered HEC or MEC.
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